Overview

Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This was a single-arm, prospective study to investigate the efficacy and safety of fruquintinib combined with sintilimab in the second-line treatment of Chinese patients with advanced gastric/GEJ adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Wuhan Union Hospital, China